Possible pharmacotherapy of the opioid κ receptor agonist for drug dependence

Annals of the New York Academy of Sciences

Volumn 1025, Issue , 2004, Pages 404-413

  Hasebe, Ko ^a   Kawai, Koji ^a   Suzuki, Tomohiko ^a   Kawamura, Kuniaki ^a   Tanaka, Toshiaki ^a   Narita, Minoru ^b   Nagase, Hiroshi ^a   Suzuki, Tsutomu ^b  

^a TORAY INDUSTRIES INC   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Drug dependence; Opioid receptor; Pharmacotherapy; TRK 820

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; COCAINE; KAPPA OPIATE RECEPTOR AGONIST; MECAMYLAMINE; MORPHINE; NALFURAFINE; NALOXONE; NALTRINDOLE; NICOTINE; NORBINALTORPHIMINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; AVERSIVE BEHAVIOR; COCAINE DEPENDENCE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPHORIA; MORPHINE ADDICTION; MOUSE; NONHUMAN; PSYCHOSIS; RAT; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALIA; RODENTIA;

EID: 10444242599     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1316.050     Document Type: Conference Paper

References (36)

1. KOOB, G.F. 1992. Drug of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13: 177-184.
2. DI CHIARA, G. & A. IMPERATO. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentration in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85: 5274-5278.
3. SUZUKI, T. 1996. Conditioned place preference in mice. Methods Find. Exp. Clin. Pharmacol. 18: 75-83.
4. PIERCEY, M.F., R.A. LAHTI, L.A. SCHROEDER, et al. 1982. U-50488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse. Life Sci. 31: 1197-1200.
5. FALLON, J.H. & F.M. LESLIE. 1994. Distribution of dynorphin and enkephalin peptides in rat brain. J. Comp. Neurol. 249: 293-336.
6. SHIPPENBERG, T.S., V.I. CHEFER, A. ZAPATA, et al. 2001. Modulation of the behavioral and neurochemical effects of psychostimulants by κ-opioid receptor systems. Ann. N.Y. Acad. Sci. 937: 50-73.
7. GLICK, S.D., I.M. MAISONNEUVE, J. RAUCCI, et al. 1995. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681: 147-152.
8. NARITA, M., Y. TAKAHASHI, K. TAKEMORI, et al. 1993. Effects of kappa-agonist on the antinociceptive and locomotor enhancing action induced by morphine in mice. Jpn. J. Pharmacol. 62: 15-24.
9. SPANAGEL, R. & M. SHOAIB. 1994. Involvement of mesolimbic kappa-opioid systems in the discriminative stimulus effects of morphine. Neuroscience 63: 797-804.
10. NARITA, M., T. SUZUKI, M. FUNADA, et al. 1993. Blockage of the morphine-induced turnover of dopamine on the mesolimbic dopaminergic system by kappa-opioid receptor activation in mice. Life Sci. 52: 397-404.
11. SUZUKI, T., Y. SHIOZAKI, Y. MATSUKAWA, et al. 1992. The role of mu- and kappa-opioid receptors in cocaine-induced place preference. Jpn. J. Pharmacol. 58: 435-442.
12. SHIPPENBERG, T.S., A. LEFEVOUR & C. HEIDBREDER. 1996. Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 276: 545-554.
13. NEGUS, S.S., N.K. MELLO, P.S. PORTOGHESE, et al. 1997. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 282: 44-55.
14. HEIDBREDER, C.A., D. BABOVIC-VUKSANOVIC, M. SHOAIB, et al 1995. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists. J. Pharmacol. Exp. Ther. 275: 150-163.
15. SUZUKI, T., T. MORI, M. TSUJI, et al. 1997. Differential effects of mu-, delta- and kappa-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats. Eur. J. Pharmacol. 324: 21-29.
16. KOOB, G.F. & F. WEISS. 1992. Neuropharmacology of cocaine and ethanol dependence. Recent Dev. Alcohol. 10: 201-233.
17. SMILEY, P.L., M. JOHANSON, L. BUSH, et al. 1990. Effects of cocaine on extrapyramidal and limbic dynorphin systems. J. Pharmacol. Exp. Ther. 253: 938-943.
18. ISE, Y., M. NARITA, H. NAGASE, et al. 2000. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacology 151: 49-54.
19. ISE, Y., M. NARITA, H. NAGASE, et al. 2002. Modulation of κ-opioidergic systems on the mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neurosci. Lett. 323: 164-166.
20. COSTALL, B., M.E. KELLY, R.J. NAYLOR, et al. 1989. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol. Biochem. Behav. 33: 197-203.
21. ADAMSON, P., J.Z. XIANG, T. MANTZOURIDES, et al. 1989. Presynaptic α2-adrenoceptor and κ-opioid receptor occupancy promotes closure of neuronal (N-type) calcium channels. Eur. J. Pharmacol. 174: 63-70.
22. CUI, Y.L., T.F. LEE & L.C.H. WANG. 1994. Species difference in the modulatory effect of κ agonist on 5-HT release from ground squirrel and rat hippocampus. Neurosci. Lett. 175: 126-128.
23. PRIVETTE, T.H. & D.M. TERRAIN. 1995. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus maze. Psychopharmacology 118: 444-450.
24. SUZUKI, T., Y. ISE, T. MORI, et al. 1997. Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron. Life Sci. 62: 249-254.
25. SCHENK, S. & B. PARTRIDGE. 2001. Effect of kappa-opioid receptor agonist, U-69593, on reinstatement of extinguished amphetamine self-administration behavior. Pharmacol. Biochem. Behav. 68: 629-634.
26. MATSUZAWA, S., T. SUZUKI, M. MISAWA, et al 1999. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress. Eur. J. Pharmacol. 368: 9-16.
27. WADENBERG, M.L. 2003. A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev. 9: 187-198.
28. FUNADA, M., T. SUZUKI, M. NARITA, et al. 1993. Blockage of morphine reward through the activation of κ-opioid receptors in mice. Neuropharmacology 32: 1315-1323.
29. NAGASE, H., J. HAYAKAWA, K. KAWAMURA, et al. 1998. Discovery of a structurally novel opioid κ-agonist derived from 4, 5-epoxymorphinan. Chem. Pharm. Bull. 46: 366-369.
30. ENDOH, T., H. MATSUURA, A. TAJIMA, et al. 1999. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist. Life Sci. 65: 1685-1694.
31. TSUJI, M., M. YAMAZAKI, H. TAKEDA, et al. 2000. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur. J. Pharmacol. 394: 91-95.
32. TSUJI, M., H. TAKEDA, T. MATSUMIYA, et al. 2001. The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68: 1717-1725.
33. SEKI, T., S. AWAMURA, C. KIMURA, et al. 1999. Pharmacological properties of TRK-820 on cloned μ-, δ- and κ-opioid receptors and nociceptin receptor. Eur. J. Pharmacol. 376: 159-167.
34. TSUJI, M., H. TAKEDA, T. MATSUMIYA, et al. 2000. A novel κ-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci. 66: 353-358.
35. MORI, T., M. NOMURA, H. NAGASE, et al. 2002. Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology 161: 17-22.
36. STALEY, J.K., R.B. ROTHMAN, K.C. RICE, et al. 1997. Kappa2 opioid receptors in limbic area of the human brain are upregulated by cocaine in fetal overdose victims. J. Neurosci. 17: 8225-8233.